Last Updated: 2/19
Share or print this information to talk to your doctor about this trial.
The primary objective of this study is to determine whether ACH-0144471 can increase blood C3 levels in participants with low C3 levels due to either C3G or IC-MPGN.
16 to 65
NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
The Royal Melbourne Hospital
Amalia Children’s Hospital
Radboud University Nijmegen Medical Centre
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
Clinical Operations | 203-752-5566
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
Continued use of this site indicates you have accepted this policy.